These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

56 related articles for article (PubMed ID: 8445951)

  • 21. A randomized phase II study of low-dose cytosine arabinoside (LD-AraC) plus granulocyte-macrophage colony-stimulating factor (rhGM-CSF) in myelodysplastic syndromes (MDS) with a high risk of developing leukemia. EORTC Leukemia Cooperative Group.
    Gerhartz HH; Marcus R; Delmer A; Zwierzina H; Suciu S; Dardenne M; Solbu G; de Witte T; Jacobs A; Visani G
    Leukemia; 1994 Jan; 8(1):16-23. PubMed ID: 8289481
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recombinant human erythropoietin in patients with myelodysplastic syndromes.
    Schouten HC; Vellenga E; van Rhenen DJ; de Wolf JT; Coppens PJ; Blijham GH
    Leukemia; 1991 May; 5(5):432-6. PubMed ID: 2033964
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies.
    Yee KW; Zeng Z; Konopleva M; Verstovsek S; Ravandi F; Ferrajoli A; Thomas D; Wierda W; Apostolidou E; Albitar M; O'Brien S; Andreeff M; Giles FJ
    Clin Cancer Res; 2006 Sep; 12(17):5165-73. PubMed ID: 16951235
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Systematic preclinical study on the therapeutic properties of recombinant human interleukin 2 for the treatment of metastatic disease.
    Talmadge JE; Phillips H; Schindler J; Tribble H; Pennington R
    Cancer Res; 1987 Nov; 47(21):5725-32. PubMed ID: 3499218
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Busulfan, cyclophosphamide and melphalan as conditioning regimen for bone marrow transplantation in children with myelodysplastic syndromes.
    Locatelli F; Pession A; Bonetti F; Maserati E; Prete L; Pedrazzoli P; Zecca M; Prete A; Paolucci P; Cazzola M
    Leukemia; 1994 May; 8(5):844-9. PubMed ID: 8182940
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A phase II trial of interleukin-2 in myelodysplastic syndromes.
    Nand S; Stock W; Stiff P; Sosman J; Martone B; Radvany R
    Br J Haematol; 1998 Apr; 101(1):205-7. PubMed ID: 9576203
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Myelodysplastic syndromes in childhood. Report of 21 patients from Italy and West Germany.
    Creutzig U; Cantù-Rajnoldi A; Ritter J; Romitti L; Odenwald E; Conter V; Riehm H; Masera G
    Am J Pediatr Hematol Oncol; 1987; 9(4):324-30. PubMed ID: 3439582
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia.
    Hofmann WK; Heil G; Zander C; Wiebe S; Ottmann OG; Bergmann L; Hoeffken K; Fischer JT; Knuth A; Kolbe K; Schmoll HJ; Langer W; Westerhausen M; Koelbel CB; Hoelzer D; Ganser A
    Ann Hematol; 2004 Aug; 83(8):498-503. PubMed ID: 15156346
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combination of 5-azacytidine and thalidomide for the treatment of myelodysplastic syndromes and acute myeloid leukemia.
    Raza A; Mehdi M; Mumtaz M; Ali F; Lascher S; Galili N
    Cancer; 2008 Oct; 113(7):1596-604. PubMed ID: 18720364
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Erythroderma disclosing transformation of refractory anemia with excess of blasts into lymphoblastic leukemia].
    Bodokh I; Lacour JP; Perrin C; Rosenthal E; Garnier G; Pesce A; Ortonne JP
    Ann Dermatol Venereol; 1993; 120(4):303-4. PubMed ID: 8239380
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cytogenetic evolution following the transformation of myelodysplastic syndrome to acute myelogenous leukemia: implications on the overlap between the two diseases.
    Ghaddar HM; Stass SA; Pierce S; Estey EH
    Leukemia; 1994 Oct; 8(10):1649-53. PubMed ID: 7934160
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Successful treatment of refractory anemia with excess of blasts in transformation with cytarabine ocfosfate].
    Takeuchi M; Kojima K; Takaba S; Isokawa M; Tanimizu M; Kimura F; Ohmoto E; Harada M
    Gan To Kagaku Ryoho; 1995 Jan; 22(1):141-4. PubMed ID: 7826071
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adding growth factors or interleukin-3 to erythropoietin has limited effects on anemia of transfusion-dependent patients with myelodysplastic syndromes unresponsive to erythropoietin alone.
    Musto P; Sanpaolo G; D'Arena G; Scalzulli PR; Matera R; Falcone A; Bodenizza C; Perla G; Carotenuto M
    Haematologica; 2001 Jan; 86(1):44-51. PubMed ID: 11146570
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Interleukin-2 induction of lymphokine-activated killer activity in the peripheral blood of an acute lymphoblastic leukaemia patient--case study.
    Dickinson AM; Lennard AL; Cartner R; Proctor SJ
    Leukemia; 1992 Sep; 6(9):957-60. PubMed ID: 1518307
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Elevated plasma soluble interleukin 2 receptor level correlates with defective natural killer and CD8+ T-cells in myelodysplastic syndromes.
    Yokose N; Ogata K; Ito T; An E; Tamura H; Dan K; Hamaguchi H; Sakamaki H; Onozawa Y; Nomura T
    Leuk Res; 1994 Oct; 18(10):777-82. PubMed ID: 7934136
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Low-dose melphalan in myelodysplastic syndromes: an effective treatment for elderly RAEB-I or II patients?
    Xiao Z; Liu L; Xu Z; Qin T; Zhang Y; Zhang T
    Leuk Lymphoma; 2010 Mar; 51(3):549-51. PubMed ID: 20038270
    [No Abstract]   [Full Text] [Related]  

  • 37. [Treatment of myelodysplastic syndrome with alfacalcidol].
    Tagawa M; Ito H; Kuriyama K; Tomonaga M; Ichimaru M
    Gan To Kagaku Ryoho; 1987 Nov; 14(11):3160-2. PubMed ID: 3674901
    [No Abstract]   [Full Text] [Related]  

  • 38. [Myelodysplasia and tuberculosis].
    Ugo V; Ramon S; Delmer A; Cadiou M; Marie JP
    Bull Cancer; 1996 Jul; 83(7):548-52. PubMed ID: 8868942
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Does interleukin-2 have a role in the management of acute leukemia?
    Foa R
    J Clin Oncol; 1993 Sep; 11(9):1817-25. PubMed ID: 8355048
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of 5-azacytidine on natural killer cell activating receptor expression in patients with refractory anemia with excess of blasts.
    Costello RT; Leclercq A; Treut TL; Sanchez C; Mercier D; Sébahoun G
    Leuk Res Rep; 2015; 4(1):15-7. PubMed ID: 25709892
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.